Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Must Reads In Genitourinary Cancer
Genitourinary Cancer for November/December 2015
Prostate Cancer Incidence Rates Since 1995, A troubling trend emerges
Androgen Deprivation Therapy in Prostate Cancer, Studying associations with dementia
Abiraterone Acetate Treatment in Prostate Cancer, How does it affect survival?
FDA Approves Opdivo for Advanced Renal Cell Carcinoma, Second line after prior antiangiogenic therapy
Genitourinary Cancer for September/October 2015
Racial Differences in Radical Prostatectomy, Comparing treatment, costs, and mortality
Racial Differences in Prostate Cancer, Studying black men and white men after radical prostatectomy
Cabozantinib in Advanced Renal-cell Carcinoma, Comparing it with everolimus
Nivolumab in Advanced Renal-cell Carcinoma, Comparing it with everolimus
Preventing Nausea, Vomiting After Chemotherapy, Complete response demonstrated with rolapitant
Genitourinary Cancer for July/August 2015
Multigene Panel Testing in BC, OC, Assessing risks beyond BRCA1/2 mutations
ADT Plus Docetaxel in Metastatic Prostate Cancer, Assessing its effect on survival
Chemotherapy Vs Surgery in Testicular Cancer, Does one carry greater risk of CVD?
Low-Grade Serous Carcinoma, Assessing the risk factors
Genitourinary Cancer for May/June 2015
Adjuvant and Neoadjuvant Radiation Therapy in Genitourinary Cancers, Tracking the usage trend